- Home
- CAPT vs NXTC Comparison
CAPT vs NXTC Comparison
Compare CAPT & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPT
- NXTC
- Stock Information
- Founded
- CAPT 2005
- NXTC 2015
- Country
- CAPT South Korea
- NXTC United States
- Employees
- CAPT N/A
- NXTC N/A
- Industry
- CAPT Blank Checks
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- CAPT Finance
- NXTC Health Care
- Exchange
- CAPT Nasdaq
- NXTC Nasdaq
- Market Cap
- CAPT 27.5M
- NXTC 24.6M
- IPO Year
- CAPT N/A
- NXTC 2019
- Fundamental
- Price
- CAPT $0.86
- NXTC $9.36
- Analyst Decision
- CAPT
- NXTC Strong Buy
- Analyst Count
- CAPT 0
- NXTC 3
- Target Price
- CAPT N/A
- NXTC $23.00
- AVG Volume (30 Days)
- CAPT 5.2M
- NXTC 97.5K
- Earning Date
- CAPT 01-01-0001
- NXTC 11-05-2025
- Dividend Yield
- CAPT N/A
- NXTC N/A
- EPS Growth
- CAPT N/A
- NXTC N/A
- EPS
- CAPT N/A
- NXTC N/A
- Revenue
- CAPT $17,389,944.00
- NXTC N/A
- Revenue This Year
- CAPT N/A
- NXTC N/A
- Revenue Next Year
- CAPT N/A
- NXTC N/A
- P/E Ratio
- CAPT N/A
- NXTC N/A
- Revenue Growth
- CAPT 84.70
- NXTC N/A
- 52 Week Low
- CAPT $0.37
- NXTC $2.69
- 52 Week High
- CAPT $1.94
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- CAPT 54.99
- NXTC 51.48
- Support Level
- CAPT $0.58
- NXTC $8.13
- Resistance Level
- CAPT $1.16
- NXTC $10.56
- Average True Range (ATR)
- CAPT 0.11
- NXTC 1.04
- MACD
- CAPT 0.03
- NXTC -0.39
- Stochastic Oscillator
- CAPT 54.68
- NXTC 24.50
About CAPT Captivision Inc.
Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.